Kura Oncology (Nasdaq: KURA) announced that on August 3, 2026, its Board Compensation Committee granted inducement awards of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees under the 2023 Inducement Option Plan, as amended.
The options have an exercise price of $9.19 per share, equal to the August 3, 2026 closing price, and vest over four years: 25% after one year and the remaining shares monthly over the following 36 months, subject to continued service. The awards were approved as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
Kura granted options to purchase 104,500 shares to six new employees, rather than issuing those shares immediately; if the underlying shares are issued, the total share count would increase and existing holders’ percentage ownership would decrease.
Market Context
KURA's prior inducement-grant event, news_id 1067417, produced a -0.34% 24-hour reaction. That recor...
Analysis
KURA's prior inducement-grant event, news_id 1067417, produced a -0.34% 24-hour reaction. That record adds a direct comparison, while Net Selling insider activity remains a sourced risk factor.
Key Figures
Grant date:August 3, 2026Shares subject to options:104,500 sharesRecipients:6 employees+4 more
7 metrics
Grant dateAugust 3, 2026Inducement stock option grants
Shares subject to options104,500 sharesSix new employees
"granted inducement awards consisting of nonstatutory stock options"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"Each stock option has an exercise price equal to $9.19 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 3, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six (6) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $9.19 per share, the closing price of the Company’s common stock on August 3, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
What inducement stock option grants did Kura Oncology (KURA) announce on August 7, 2026?
Kura Oncology announced nonstatutory stock options for 104,500 shares granted to six new employees. According to Kura Oncology, these options were issued under its 2023 Inducement Option Plan as employment inducement awards consistent with Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the new Kura Oncology (KURA) inducement stock options?
The exercise price of the new inducement stock options is $9.19 per share. According to Kura Oncology, this price equals the closing price of its common stock on August 3, 2026, the grant date for these nonstatutory options.
How do the Kura Oncology (KURA) inducement stock options vest for new employees?
The inducement options vest over four years with a back-loaded schedule. According to Kura Oncology, 25% vests on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting monthly over the following 36 months, subject to continued service.
How many employees received Kura Oncology (KURA) inducement option grants in August 2026?
Six new employees received inducement stock option grants in August 2026. According to Kura Oncology, these employees were granted options to purchase an aggregate of 104,500 shares of common stock under the company’s 2023 Inducement Option Plan, as amended.
Under which plan were the August 2026 Kura Oncology (KURA) inducement options granted?
The August 2026 inducement options were granted under Kura’s 2023 Inducement Option Plan, as amended. According to Kura Oncology, these nonstatutory stock options are also governed by individual stock option agreements specifying detailed terms and conditions for each grant.
Why were Kura Oncology (KURA) inducement stock options granted under Nasdaq Listing Rule 5635(c)(4)?
The options were granted as inducement awards material to employment under Nasdaq Listing Rule 5635(c)(4). According to Kura Oncology, this rule allows equity grants to new employees outside shareholder-approved plans when used as significant hiring incentives.
